Securities Registration: Employee Benefit Plan (s-8)
09 Mayo 2023 - 7:22AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on May 9, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Verrica Pharmaceuticals Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware |
|
46-3137900 |
(State or other jurisdiction of
Incorporation or organization) |
|
(I.R.S. Employer
Identification No.) |
44 West Gay Street, Suite 400
West Chester, PA 19380
(Address of principal executive offices) (Zip code)
2018 Equity Incentive Plan
(Full title of the plan)
Ted White
President and
Chief Executive Officer
Verrica Pharmaceuticals Inc.
44 West Gay Street, Suite 400
West Chester, PA 19380
(484) 453-3300
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Darren DeStefano
Mark
Ballantyne
Cooley LLP
11951 Freedom Drive
Reston, VA 20190-5640
(703) 456-8000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
EXPLANATORY NOTE
Pursuant to General Instruction E of Form S-8, Verrica Pharmaceuticals Inc. (the
Registrant) is filing this Registration Statement with the Securities and Exchange Commission (the Commission) to register 1,643,762 additional shares of Common Stock under the 2018 Equity Incentive Plan (the 2018
Plan), pursuant to the provisions of the 2018 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan on January 1, 2023. In accordance with the
instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration
Statement.
2
PART II
ITEM 3. |
INCORPORATION OF DOCUMENTS BY REFERENCE |
The contents of the earlier registration statement related to the 2018 Plan, previously filed with the Commission on July 13, 2018 (File No. 333-226153) are incorporated herein by reference and made a part of this Registration Statement.
3
(1) |
Previously filed as Exhibit 3.3 to the Registrants Registration Statement on Form S-1 (File No. 333-225104), filed with the Commission on May 22, 2018, and incorporated by reference herein. |
(2) |
Previously filed as Exhibit 3.4 to the Registrants Registration Statement on Form S-1 (File No. 333-225104), filed with the Commission on May 22, 2018, and incorporated by reference herein. |
(3) |
Previously filed as Exhibit 10.4 to Amendment No. 1 to the Registrants Registration Statement on
Form S-1 (File No. 333-225104), filed with the Commission on June 5, 2018, and incorporated by reference herein. |
(4) |
Previously filed as Exhibit 10.5 to Amendment No. 1 to the Registrants Registration Statement on
Form S-1 (File No. 333-225104), filed with the Commission on June 5, 2018, and incorporated by reference herein. |
4
1. |
The undersigned registrant hereby undertakes: |
(a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with
the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the
effective registration statement.
(iii) To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such information in the registration statement;
Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
(b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
2. |
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the
Securities Act, each filing of the registrants annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plans annual report pursuant to section
15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof. |
3. |
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue. |
5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of West
Chester, Commonwealth of Pennsylvania, on this 9th day of May, 2023.
|
|
|
VERRICA PHARMACEUTICALS INC. |
|
|
By: |
|
/s/ Ted White |
|
|
Ted White |
|
|
President and Chief Executive Officer |
6
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ted White and P. Terence Kohler
Jr., and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and
stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities
and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing
requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons
in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
/s/ Ted White |
|
President, Chief Executive Officer and Director |
|
May 9, 2023 |
Ted White |
|
(Principal Executive Officer) |
|
|
|
|
|
/s/ P. Terence Kohler Jr. |
|
Chief Financial Officer |
|
May 9, 2023 |
P. Terence Kohler Jr. |
|
(Principal Financial Officer and Principal Accounting Officer) |
|
|
|
|
|
/s/ Paul B. Manning |
|
Director |
|
May 9, 2023 |
Paul B. Manning |
|
|
|
|
|
|
|
/s/ Sean Stalfort |
|
Director |
|
May 9, 2023 |
Sean Stalfort |
|
|
|
|
|
|
|
/s/ Craig Ballaron |
|
Director |
|
May 9, 2023 |
Craig Ballaron |
|
|
|
|
|
|
|
/s/ Mark Prygocki |
|
Director |
|
May 9, 2023 |
Mark Prygocki |
|
|
|
|
|
|
|
/s/ Lawrence Eichenfield |
|
Director |
|
May 9, 2023 |
Lawrence Eichenfield |
|
|
|
|
|
|
|
/s/ Diem Nguyen |
|
Director |
|
May 9, 2023 |
Diem Nguyen |
|
|
|
|
7
Verrica Parmaceuticals (NASDAQ:VRCA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024